Figures & data
Figure 1. Growth inhibition of LNCaP cells by ibandronate. The cell number was measured after incubation with increasing concentrations of ibandronate for five days using the MTT assay. Values represent means ± S.D., n=4. Significant difference *=p<0.05; **=p<0.01 between two survival fractions of treated cells and control cells.
Figure 2. Growth inhibition of PC3 cells by ibandronate. The cell number was measured after incubation with increasing concentrations of ibandronate for five days using the MTT assay. Values represent means ± S.D., n=4. Significant difference *=p<0.05; **=p<0.01 between two survival fractions of treated cells and control cells.
Figure 3. Growth inhibition of LNCaP cells by docetaxel. The cell number was measured after incubation with increasing concentrations of docetaxel for five days using the MTT assay. Values represent means ± S.D., n=4. Significant difference *=p<0.05; **=p<0.01 between two survival fractions of treated cells and control cells.
Figure 4. Combination of Ibandronate and docetaxel in LNCaP. The cell number was measured after incubation with ibandronate and/or docetaxel for five days using the MTT assay. Values represent means ± S.D., n=4. Significant difference *=p<0.05; **=p<0.01 between two survival fractions of treated cells and control cells.
Figure 5. Reversibility of growth inhibition of ibandronate by addition of farnesol (FOH). The cell number of LNCaP (A) and PC-3 (B) cells was measured after incubation with ibandronate alone and in combination with increasing concentrations of FOH for five days. Values represent means ± S.D., n=4. Significant difference *=p<0.05; **=p<0.01 between two survival fractions of treated cells and control cells.
Figure 6. Growth inhibition of LNCaP by combination treatment of ibandronate, docetaxel and FOH. The cell number was measured after incubation with ibandronate, docetaxel and farnesol alone and in combination for five days, using the MTT assay. Values represent means ± S.D., n=4. Significant difference *=p<0.05; **=p<0.01 between two survival fractions of treated cells and control cells.
Figure 7. The mevalonate pathway.
